Neurogenic Bladder: Epidemiology, Diagnosis, and Management

Jalesh N. Panicker, MD, DM, FRCP1

1 Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Queen Square Institute of Neurology, London, United Kingdom

Semin Neurol 2020;40:569–579.

Address for correspondence Jalesh N. Panicker, MD, DM, FRCP, Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, Queen Square, London, United Kingdom (e-mail: j.panicker@ucl.ac.uk).

The term “neurogenic bladder” is loosely used to denote lower urinary tract (LUT) dysfunction caused by neurological disease. LUT dysfunction is commonly reported by patients with neurological disease, and the impact on quality of life is being increasingly recognized by the practicing neurologist. Its heterogeneous presentation reflects the complexity of the neural control of the LUT, and the site of lesion in the neurological axis determines the pattern of symptoms and dysfunction. Pelvic organ dysfunction encompasses LUT, sexual, and bowel dysfunction, and their complex interrelationship is now better understood, with the recognition that a holistic approach is required for management. This review presents an overview of neurological control of LUT functions in health, a clinical approach to evaluating LUT dysfunction in the context of neurological disease, and an overview of current treatment strategies.

Neurological Control of Lower Urinary Tract Functions in Health

A complex neural network acts as a switching circuit to maintain a reciprocal relationship between the reservoir...
function of the bladder and sphincter function of the urethra. This results in low-pressure filling and periodic voluntary emptying. The frequency of micturition in a person with a bladder capacity of 400 to 600 mL is once every 3 to 4 hours, and the bladder is in a storage phase more than 99% of the time.\textsuperscript{1,2} Switching from the storage to the voiding phase is initiated by a conscious decision, which is influenced by the perceived state of bladder fullness and an assessment of the social appropriateness of voiding. This phasic pattern of activity, as well as degree of voluntary control and dependence on learned behavior, is unique to the LUT compared with other autonomically innervated structures such as the cardiovascular system.\textsuperscript{1}

Connections between the pons and the sacral spinal cord, as well as the peripheral innervation that originates from the caudal spinal cord, need to be intact to effect storage and voiding. During bladder filling, sympathetic and pudendal nerves mediate contraction of the smooth (internal) and striated (external) urethral sphincter, whereas sympathetic-mediated inhibition of the detrusor prevents contractions. This results in low pressure filling and continence.\textsuperscript{1} When deemed appropriate to void, the pontine micturition center (PMC) is released from the tonic inhibition of higher cortical centers, and parasympathetic-mediated detrusor contraction accompanied by relaxation of the pelvic floor and external and internal urethral sphincters results in effective bladder emptying.\textsuperscript{3,4}

### Neurogenic Lower Urinary Tract Dysfunction

A neurourological classification of neurological disorders is useful to understand that different patterns of LUT dysfunction can arise following neurological disease (\textsuperscript{ Fig. 1}).\textsuperscript{5} Detrusor overactivity (DO) is the most common cause for urinary incontinence following neurological disease. Patients report varying degrees of storage symptoms such as urinary urgency, frequency, nocturia, and incontinence (collectively known as “overactive bladder symptoms”). Damage to central inhibitory pathways or sensitization of peripheral afferent terminals in the bladder can unmask primitive voiding reflexes and be expressed as spontaneous involuntary contractions of the detrusor.\textsuperscript{6} The mechanisms for detrusor overactivity following suprapontine damage are, however, different from those following spinal cord injury (SCI). A lesion affecting the suprapontine neural network...
results in removal of the tonic inhibition of the PMC and involuntary detrusor contractions. Detrusor overactivity occurring following a lesion of the suprasacral spinal cord is mediated through the emergence of a spinal reflex pathway that triggers bladder overactivity. Afferent nerves conveying sensations from the LUT to the spinal cord contain unmyelinated C-fibers that have a much greater threshold for activation and are therefore quiescent in health. Following SCI, the C-fibers become sensitized and are mechanosensitive at lower bladder volumes. A segmental spinal reflex emerges that is mediated by C-fibers afferents nerves and results in involuntary detrusor contractions, the basis for NDO. LUT, lower urinary tract; NDO, neurogenic detrusor overactivity. (Used with permission from Panicker et al.\textsuperscript{7})

Parkinson’s Disease and Multiple System Atrophy
The prevalence of LUT symptoms in Parkinson’s disease ranges between 38 and 71\%, depending on the extent and duration of disease. LUT symptoms are the commonest non-motor symptoms reported in PD,\textsuperscript{9} and are associated with an increased risk for falls,\textsuperscript{10} early institutionalization, and escalating health-related costs.\textsuperscript{11} Nocturia is the most common LUT symptom and can arise due to impaired bladder storage from DO and from nocturnal polyuria.\textsuperscript{12,13} In multiple system atrophy (MSA), LUT symptoms occur early in the course, often preceding other neurological manifestations and even orthostatic hypotension.\textsuperscript{14} Incontinence arises from detrusor overactivity and external sphincter weakness; however, as the disease progresses, incomplete bladder emptying becomes the predominant feature.\textsuperscript{15} The finding of an open bladder neck in videourodynamic studies in men who have not undergone surgery to the bladder outlet is a suggestive sign of sympathetic denervation of the bladder neck seen in MSA.\textsuperscript{16}

Dementia
Incontinence is often a prominent symptom and contributes significantly to caregiver’s burden. Incontinence occurs early in normal pressure hydrocephalus, dementia with Lewy’s bodies, vascular dementia, and frontotemporal dementia, whereas it generally occurs late in the course of Alzheimer’s disease or Parkinson’s disease with dementia.\textsuperscript{17,18} In patients with dementia and incontinence, pharmacological treatment of one condition can exacerbate the other.\textsuperscript{19} Incontinence may result not only from detrusor overactivity, but also from cognitive and behavioral problems, urological comorbidities, and immobility.

Cerebrovascular Disease
More than half of stroke patients report urinary incontinence during the acute phase of stroke. Risk factors for incontinence include large lesion size and the presence of comorbid
illnesses such as diabetes and older age. Lesions in the anteromedial frontal lobe, periventricular white matter, and putamen are most commonly associated with LUT symptoms. Most commonly, urodynamic studies show evidence for detrusor overactivity. Urinary retention has been reported following hemorrhagic and ischemic stroke. There is evidence to suggest that incontinence is independently associated with subsequent severity of neurological disability, institutionalization, and mortality. Small vessel disease of the white matter, leukoaraiosis, is associated with urgency incontinence, and it is now apparent that this is an important cause for incontinence in the functionally independent elderly.

**Multiple Sclerosis**
Lower urinary tract symptoms are reported in 32 to 96% of patients with MS, depending on the duration and severity of disease. Symptoms are reported on average six years into the illness, and more than 90% of patients report symptoms if the duration of disease exceeds 10 years. Symptoms may be overlooked, however, and the results of a recent survey suggest that nearly half of MS patients with moderate-to-severe overactive bladder symptoms had not undergone an evaluation by a urologist. Relevant to a neurology practice is that 10% of patients report LUT symptoms at the time of initial diagnosis. Most patients classify the impact symptoms have on their life as moderate or high, and urinary incontinence is considered to be one of the worst aspects of the disease. Most commonly, both storage and voiding symptoms are reported. The most common findings in urodynamic testing are DO and DSD.

**Spinal Cord Injury**
During the stage of spinal shock, patients are often in urinary retention. They develop the typical pattern of DO and DSD over time as spinal reflexes return. Pressures within the bladder may rise considerably, increasing the risk for upper urinary tract damage. Urinary retention, bladder spasms, UTIs, interventions of the bladder and bowel, constipation, and sexual activity can trigger autonomic dysreflexia in individuals with lesions at the T6 spinal cord level or above.

**Spina Bifida**
Lower urinary tract dysfunction is common in spina bifida, reported in more than 90% of children. Dysfunction begins in utero, and symptoms usually manifest soon after birth, though may be delayed until childhood, and occasionally until adulthood. Urodynamic studies demonstrate a variety of findings including detrusor overactivity, detrusor underactivity or low compliance, DSD, or a static or fixed external urethral sphincter. Young individuals may develop LUT dysfunction later on in life due to spinal cord tethering. They should therefore be regularly monitored, as they may be at risk for developing upper urinary tract complications.

**Cauda Equina Syndrome and Peripheral Neuropathy**
Reduced or absent detrusor contractions are commonly seen. Individuals report reduced sensation of bladder fullness, inability to initiate micturition voluntarily, and bladder distension, to the point of overflow incontinence. Detrusor overactivity may, however, occur in a subset of patients, and this may be as a result of “bladder decentralization” due to preserved peripherally sited postganglionic neurons.

---

**Table 1** The differential diagnosis for urinary retention in a patient where a structural urological lesion has been excluded

| Category                                      | Subcategories                                                                 |
|-----------------------------------------------|-------------------------------------------------------------------------------|
| 1. Lesions of the conus medullaris or cauda equina | Compressive lesions, Spine fracture, Intervertebral disc prolapse, Space-occupying lesions—tumor, granuloma, abscess, Vascular—infarction, AV malformation with vascular steal, Inflammation—myelitis, meningitis retention syndrome, Infection—herpes simplex, varicella zoster, cytomegalovirus, Elsberg’s syndrome (viral aseptic meningitis) |
| 2. Other neurological conditions              | Spina bifida, Multiple system atrophy, Autonomic failure, e.g., pure autonomic failure, autonomic neuropathies |
| 3. Miscellaneous                              | Medications, e.g., opioids, anticholinergics, retigabine, Radical pelvic surgery, Fowler’s syndrome (females) |

Abbreviation: AV, arteriovenous malformation.
Urinary Retention
Urinary retention may occur following neurological disease (→Table 1). Medications such as opiates, those with anticholinergic properties (e.g., neuroleptics, tricyclic antidepressants, respiratory agents with anticholinergic effects, and antimuscarinic agents for the bladder) and α-adrenoceptor agonists may cause voiding dysfunction, ranging from incomplete bladder emptying to complete urinary retention. Conversely, in patients with progressive nontraumatic neurological disorders, such as Parkinson’s disease or multiple sclerosis, who are typically at low risk for upper urinary tract involvement, the management is focused on symptomatic control of neurogenic LUT dysfunction.

Impact of Lower Urinary Tract Dysfunction on the Upper Urinary Tract
In some individuals, high pressures within the LUT may affect the upper urinary tract, resulting in vesicoureteric reflux, hydronephrosis, and in some instances renal impairment and end-stage renal disease. Patients with SCI or spina bifida are at significant risk of developing these problems, having a five or eight times risk, respectively, of developing renal failure compared with the general adult population. For reasons that are not fully understood, the prevalence of upper urinary tract damage and renal failure is much lower in patients with slowly progressive nontraumatic neurological disorders. In patients with multiple sclerosis, the risk for urinary tract complications is higher with increasing disease duration and severity of disability, as is also the case for patients with Parkinson’s disease and hereditary spastic paraplegia. The management of neurogenic LUT dysfunction should include a risk assessment of developing upper urinary tract damage: in patients at high risk of upper urinary tract damage, management is focused on life-long frequent urological evaluations to define the need for interventions to reduce the risk of complications. Evaluation
A multidisciplinary approach involving neurologists, urologists, physiatrists, and primary care physicians is key to successful management of LUT dysfunction (→Table 2).

| Table 2 | Assessment of the patient with neurological disorders reporting LUT symptoms |
|---------|--------------------------------------------------------------------------------|
| **Bedside evaluation** | **Noninvasive tests** | **Invasive tests** |
| Essential | • History taking | • Urinalysis | N/A |
| | • Physical examination | • PVR measurement Ultrasonography | |
| | • Bladder diary | | |
| Desirable | Questionnaires | • Uroflowmetry | N/A |
| | | • Blood biochemistry | |
| Required in specific situations | N/A | • Urine culture | | • (Video-) urodynamics |
| | | • Urine cytology | • Cystoscopy |
| | | | • Pelvic neurophysiology |
| | | | • Renal scintigraphy |

Abbreviation: LUT, lower urinary tract. (Used with permission from Panicker et al.)
In patients known to be at high risk of upper urinary tract disease, ultrasonography should be performed periodically to screen for upper urinary tract dilatation or renal scarring. Ultrasound may also be used to demonstrate urinary tract stones, which may develop in patients with neurogenic LUT dysfunction.

Urodynamic Investigations

Noninvasive Urodynamic Tests
Uroflowmetry provides a valuable noninvasive assessment of voiding functions, and the PVR is usually measured with the test. The pattern and rate of flow depend on detrusor function and bladder outlet resistance.

Invasive Urodynamic Tests
Combined cystometry and pressure-flow study, with or without simultaneous fluoroscopic monitoring (i.e., videourodynamics), assess detrusor and bladder outlet function and provide information about detrusor pressure and compliance. Urodynamic testing helps establish the pathophysiological basis for LUT symptoms, but also serves as a tool to assess risk for upper tract damage as discussed earlier.

The place of urodynamics in the evaluation of LUT symptoms in neurological patients is a matter of ongoing debate. For example, in the assessment of LUT functions in patients with early multiple sclerosis, urodynamic studies are recommended by the French guidelines, whereas in the United Kingdom, the recommended first-line management involves testing for urinary tract infections (UTIs) and PVR measurement without invasive urodynamics. In the absence of studies comparing these two models, the decision to perform complete baseline urodynamic studies would depend on local recommendations and resources.

Other Tests
Other LUT pathologies may coexist with LUT symptoms, and cystoscopy (combined with bladder washing cytology if appropriate) is indicated when urethral stricture, bladder stones, and bladder tumors are suspected.

Measuring serum creatinine and calculating the estimated glomerular filtration rate (GFR) yield a reasonable estimation of renal function with minimal cost and inconvenience. The GFR is most accurately measured using renal scintigraphy, which is recommended when renal function is poor, in individuals with reduced muscle mass, if function for each renal unit has to be assessed separately and in high-risk patients.

Pelvic Neurophysiology
The role of pelvic EMG in the assessment of individuals with established neurological disease is limited. Pelvic floor EMG was first introduced as part of urodynamic studies with the aim of recognizing DSD. However, it is less commonly performed nowadays with the advent of video-urodynamics testing. Sphincter muscle EMG is useful in evaluating the innervation of the sacral second, third, and 4th innervation, when cauda equina syndrome is suspected, or sometimes in patients presenting with a parkinsonian syndrome to aid in the differential diagnosis between idiopathic Parkinson’s disease and MSA. Urethral sphincter EMG has proven to be useful in the evaluation of young women in urinary retention when Fowler’s syndrome is suspected.

Management
The goals of management are to achieve urinary continence, improve quality of life, prevent UTIs, and preserve upper urinary tract function. The management of neurogenic LUT dysfunction should address both voiding and storage dysfunction, and is influenced by the severity of symptoms and risk for developing upper urinary tract damage. Adopting an approach that includes evaluating LUT symptoms, risk assessment for upper tract impairment, and regular review after instituting treatment provides a framework for the practicing neurologist to manage LUT dysfunction in their patients.

Table 3 Treatment options for bladder dysfunction

| Storage dysfunction | Voiding dysfunction |
|---------------------|---------------------|
| **Urgency, frequency ± incontinence** | **Stress incontinence** |
| **Conservative** | Pelvic floor muscle exercises |
| • Behavioral therapy | • Intermittent catheterization |
| • Antimuscarinic agents | • Indwelling catheterization |
| • Desmopressin | • Triggered voiding |
| • OnabotulinumtoxinA into the detrusor | • Alpha-blockers |
| • Beta-3-receptor agonists | • OnabotulinumtoxinA into the external sphincter |
| • Tibial neuromodulation | |
| **Surgical** | |
| • Sacral neuromodulation | • Bulking agents |
| • Bladder augmentation | • Autologous/synthetic slings |
| • Sacral deafferentation/anterior root stimulation | • Balloons |
| | • Artificial sphincter |
| **Continent/incontinent urinary diversion** | • Sacral neuromodulation |
| | • Intraurethral stents |
| | • External sphincter/bladder neck incision |
| | • Transurethral resection of prostate |

(Used with permission from Panicker et al.)
patients with progressive nontraumatic neurological disorders. Table 3 presents the different treatment options.

Managing Storage Dysfunction

Antimuscarinic Agents

Competitive antagonism of the muscarinic receptors results in detrusor relaxation and lower intravesical pressures. Since the introduction of oxybutynin, several newer antimuscarinic agents have appeared on the market (Table 5) and have been shown to be efficacious in neurogenic OAB.44–48 The findings of systematic reviews suggest that the only difference between medications is their side effect profile.49,50 Prescribing patterns of these agents are determined by local guidance.

The common adverse effects include dry mouth, blurred vision for near objects, constipation, and occasionally tachycardia. These symptoms are often reported by individuals already with neurological disease and therefore must be reviewed before commencing the medication. The PVR may increase after starting an antimuscarinic agent, and therefore should be monitored in case of a poor response to treatment or paradoxical worsening of symptoms.39 Several of the antimuscarinic agents can cross the blood–brain barrier, and through their effects on central muscarinic receptors can result in adverse effects such as alterations in cognition and consciousness. Increasing the anticholinergic burden from cumulative use of medications with anticholinergic properties may be associated with worsening cognitive functions, MRI findings of brain atrophy, decline in physical functions, and falls.51–53 In susceptible individuals such as the elderly, it would appear sensible to recommend the use of an antimuscarinic agent with minimal effects on the central muscarinic receptors. Trospium chloride is relatively impermeable to the blood–brain barrier because of its physicochemical properties, and darifenacin has greater affinity for the M3 receptor subtype of relevance to the LUT compared with the M1 subtype, which is prevalent in the brain.54–56 However, evidence supporting their use in clinical practice based on this consideration is limited.57

Beta-3-Adrenergic Receptor Agonists

The β-3-adrenergic receptor agonist mirabegron has been approved for managing overactive bladder symptoms. Although devoid of the adverse effects reported with antimuscarinic agents, side effects do occur, including palpitations, hypertension, and, rarely, atrial fibrillation.58 Studies suggest that mirabegron is efficacious in patients

Table 4 Red flags warranting a referral to a urology service

| Red flags warranting a referral to a urology service |
|-----------------------------------------------------|
| • Hematuria                                          |
| • Recurrent urinary tract infections                 |
| • Pain suspected to be originating from the urinary tract |
| • Increased risk for upper urinary tract damage, or findings of upper tract damage or renal impairment in imaging or blood tests |
| • Suspicion of concomitant urological or gynecological pathologies, e.g., bladder outlet obstruction due to prostate enlargement in men or stress incontinence in women |
| • Lower urinary tract symptoms refractory to conservative treatments—consideration of more invasive treatments such as intradetrusor injections of botulinum toxin A or surgery, or when suprapubic catheterization appears appropriate |

Table 5 Commonly used antimuscarinic agents

| Antimuscarinic agent | Preparation  | Dosage (mg) | Frequency               |
|----------------------|--------------|-------------|-------------------------|
| Darifenacin          | Controlled release | 7.5–15     | Once daily              |
| Fesoterodine         | Controlled release | 4–8  | Once daily              |
| Oxybutynin           | Immediate release | 2.5–5      | Two or three times a day |
|                      | Controlled release | 5–20     | Once daily              |
|                      | Transdermal patch | 36, releasing oxybutynin ~3.9 mg/24h | Replace once every 3–4d |
| Propiverine          | Immediate release | 15         | One to three times daily |
|                      | Controlled release | 30        | Once daily              |
| Solifenacin          | Controlled release | 5–10       | Once daily              |
| Tolterodine          | Immediate release | 2–4        | Once or twice daily     |
|                      | Controlled release | 4         | Once daily              |
| Trospium chloride    | Immediate release | 20         | Twice daily (before food) |
|                      | Controlled release | 60        | Once daily              |
with Parkinson’s disease, MS, and SCI, with tolerable side effect profiles.59–61

**Desmopressin**

Desmopressin, a synthetic analogue of arginine vasopressin, promotes fluid re-absorption at the distal and collecting tubules of the kidney and thereby temporarily reduces urine production and volume-related detrusor overactivity. It is useful for the treatment of urinary frequency or nocturia in patients with MS, providing symptom relief for up to 6 hours.62 It is also helpful in managing nocturnal polyuria, a disorder seen in patients with Parkinson’s disease and also various neurological conditions associated with orthostatic hypotension. However, it should be prescribed with caution due to the high risk of severe hyponatremia and congestive heart failure.

**Botulinum Toxin**

Since the first reports of the use of botulinum toxin injections into the detrusor in patients with SCI,63,64 several studies have been performed demonstrating the treatment to be highly effective, safe, and well tolerated, culminating in two pivotal phase 3 studies of onabotulinumtoxinA.65,66 Benefits seem to occur regardless of the underlying neurological disorder; however, data on conditions other than SCI and MS are scarce. A dose of 200 units of onabotulinumtoxinA is injected in the bladder wall, requiring cystoscopy, an intervention that can be performed under local anesthesia in most neurological patients. Long-term data confirm the efficacy of repeat onabotulinumtoxinA injections,67,68 and cost-effectiveness is superior to best supportive care.38

**Neuromodulation**

Electrical stimulation of the sacral nerve roots, tibial nerve, pudendal nerve, and dorsal genital nerves has been shown to be effective in managing the idiopathic overactive bladder. Electrical stimulation of the tibial nerve has been shown to be a safe and effective treatment for LUT storage symptoms and for bowel dysfunction.69 Stimulating the nerve using a fine gauge needle (percutaneous tibial nerve stimulation, PTNS) has been shown to improve overactive bladder symptoms and urodynamic parameters in patients with MS and PD.70,71 A typical treatment course consists of using a fixed frequency electrical signal for 30 minutes over the course of 12 sessions. PTNS is a minimally invasive option for managing patients with mild/moderate overactive bladder symptoms, and is associated with few adverse effects. Moreover, it is one of the few options for the overactive bladder not associated with worsening voiding dysfunction and incomplete bladder emptying.72 However, effects are relatively short lived, and the need to return for maintenance top-up treatments is influenced by the degree of improvement of LUT symptoms.73 Alternatively, the nerve can be stimulated using a cutaneous electrode (transcutaneous tibial nerve stimulation), and therefore may be performed at home. This treatment has been shown to be safe and effective in patients with MS or stroke experiencing urgency incontinence.74,75

**Managing Voiding Dysfunction**

Voiding dysfunction may not be apparent from history, and measuring the PVR therefore is integral. A significantly high residual urine after voiding may exacerbate detrusor overactivity, thereby worsening storage symptoms and rendering treatments such as antimuscarinics and botulinum toxin less effective. Moreover, a high PVR volume predisposes the patient to recurrent UTIs.75 If the PVR is found to be consistently elevated, catheterization, preferably intermittently, is indicated and greatly improves management.43 The PVR volume at which intermittent self-catheterization should be initiated lacks consensus, however. Many patients with neurogenic LUT dysfunction have a reduced bladder capacity, and therefore a PVR consistently more than 100 mL is often taken as the amount of residual urine that warrants treatment if the patient is symptomatic.39 A trained health care professional such as a continence advisor should assess whether neurological deficits (poor manual dexterity, weakness, tremor, rigidity, spasticity, impaired visual acuity, or cognitive impairment) may be barriers to successful catheterization.77 The frequency of catheterization depends on several factors, such as bladder capacity, fluid intake, PVR, and urodynamic parameters. Patients in complete urinary retention will need to catheterize four to six times per 24 hours. The incidence of symptomatic UTIs is low when performed regularly.39,76 In patients not suitable for intermittent catheterization, a urethral or (preferably) suprapubic indwelling catheter would need to be considered.

Triggered reflex voiding can occasionally be achieved by provoking a bladder contraction, such as suprapubic tapping and thigh scratching, and is most successful in patients with a suprasacral spinal cord lesion. However, these maneuvers should be used with caution as they may provoke a rise in intravesical pressures.28 Likewise, bladder expression using Valsalva or Créde maneuvers is usually not recommended.28 Suprapubic vibration using a mechanical “buzzee”28 and the use of α-adrenergic blockers have been advocated by some groups.39 Botulinum toxin injections into the external urethral sphincter may improve bladder emptying in patients with SCI who have significant voiding dysfunction.79

**Surgical Treatment**

Surgical interventions should be considered in cases where these first- and second-line treatments have failed. Nowadays, surgery is increasingly becoming uncommon for progressive nontraumatic neurological conditions due to the availability of less invasive options (Table 3).5

**Follow-up of Patients with Neurogenic Lower Urinary Tract Dysfunction**

In the absence of long-term natural history studies, there is a lack of consensus about how often patients with neurogenic LUT dysfunction should be followed up. The population with high risk for upper tract damage should be followed up more regularly, with a patient-tailored approach aiming to achieve an optimal quality of life and to protect the upper urinary tract.
Urinary Tract Infections in Neurological Patients

Recurrent UTIs, defined as more than two UTIs in 6 months, or more than three in a year, commonly occur in neurological patients and are an important cause for hospital admissions. It is important to distinguish recurrent infections from persisting infections, as undertreatment of the latter may result in chronic infections. A high PVR can predispose to UTIs, and the incidence of symptomatic UTIs often falls when intermittent catheterization is performed regularly.

An evaluation would include assessing for incomplete bladder emptying (e.g., bladder outflow obstruction, reduced detrusor contractility) or a structural abnormality (foreign body in bladder, bladder stone, tumor, etc.), and for this reason the input of a urologist would be valuable. In individuals with proven recurrent UTIs and in whom no urological structural abnormality has been identified, it would be reasonable to initiate nonantibiotic options such as cranberry extract tablets or D-mannose. Prophylactic low-dose antibiotics for a finite duration may be required; rotating between antibiotics is one approach for minimizing the development of antibiotic resistance. The benefit of cranberry juice in preventing UTIs in neurogenic patients is debatable.

Conclusion

LUT dysfunction is common in neurological patients and has a significant impact on quality of life. Neurologists are increasingly enquiring about LUT functions and becoming involved in the management of these complaints. However, collaboration with other specialists including urologists is highly recommended to maximize patients’ quality of life.

Conflict of Interest
J.N.P. reports other from Wellspect, Astellas, and from Novartis and grants from Parkinson’s UK and Cambridge University Press, outside the submitted work.

Acknowledgments
J.N.P. undertook this work at UCLH/UCL Institute of Neurology and is supported in part by funding from the United Kingdom’s Department of Health NIHR Biomedical Research Centers funding scheme.

References
1 Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9(06):453–466
2 Fowler CJ. Integrated control of lower urinary tract–clinical perspective. Br J Pharmacol 2006;147(Suppl 2):S14–S24
3 Griffiths DJ. The pontine micturition centres. Scand J Urol Nephrol Suppl 2002;(210):21–26
4 Michels L, Blok BF, Gregorini F, et al. Supraspinal control of urine storage and micturition in men—an IMRI study. Cereb Cortex 2015;25(10):3369–3380
5 Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol 2015;14(07):720–732
6 de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50(6A, Suppl): discussion 53–5636–52
7 Panicker JN, Seth JH. C-fibre sensory nerves - not so silent as we think? BJU Int 2013;112(01):129–130
8 de Groat WC, Kawatani M, Hisamitsu T, et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990;30(Suppl):S71–S77
9 Martinez-Martín P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22(11):1623–1629
10 Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors. J Neurol 2005;252(11):1310–1315
11 McGrother CW, Jagger C, Clarke M, Castleden CM. Handicaps associated with incontinence: implications for management. J Epidemiol Community Health 1990;44(03):246–248
12 Smith M, Seth J, Batla A, Hofreiter J, Bhatia KP, Panicker JN. Nocturia in patients with Parkinson’s disease. Mov Disord Clin Pract (Hoboken) 2015;3(02):168–172
13 Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini HParkinsson’s Disease Subcommittee, The Neuromodulation Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurol Urodyn 2016;35(05):551–563
14 Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res 2019;29(06):627–631
15 Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson’s disease. Mov Disord 2010;25(01):2–12
16 Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001;71(05):600–606
17 Sakakibara R, Kanda T, Sekido T, et al. Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. Neurol Urodyn 2008;27(06):507–510
18 Ransmayr GN, Holliger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 2008;70(04):299–303
19 Sink KM, Thomas J III, Xu H, Craig B, Krichtevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008;56(05):847–853
20 Han KS, Heo SH, Lee SJ, Jeon SH, Yoo KH. Comparison of urodynamics between ischemic and hemorrhagic stroke patients; can we suggest the category of urinary dysfunction in patients with cerebrovascular accident according to type of stroke? Neurourol Urodyn 2010;29(03):387–390
21 Kuchel GA, Mosculo N, Guttmann CR, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2009;64(08):902–909
22 Tadic SD, Griffiths D, Murrin A, Schaefer W, Aizenstein HJ, Resnick NM. Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinence. Neuroimage 2010;51(04):1294–1302
23 Sakakibara R, Hattori T, Yasuda K, Yamanishi K. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci 1996;137(01):47–56
24 de Séze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe BGE-NULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13(07):915–928
25 Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol 2010;183 (04):1432–1437

26 Hemmert L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004;97(10):671–676

27 Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 2016;13 (05):275–288

28 Blok B, Pannek J, Castro-Diaz D, et al. Guidelines on Neuro-Urology. European Association of Urology; 2015

29 Podnar S, Fowler C. Pelvic organ dysfunction following cauda equina damage. In: Fowler C, Panicker J, Emmanuel A, eds. Pelvic Organ Dysfunction in Neurological Disease Clinical Management and Rehabilitation. Cambridge: Cambridge University Press; 2010

30 Smith MD, Seth JH, Fowler CJ, Miller RF, Panicker JN. Urinary retention for the neurologist. Pract Neurol 2013;13(05):288–291

31 Panicker JN, Game X, Khan S, et al. The possible role of opiates in women with chronic urinary retention: observations from a prospective clinical study. J Urol 2012;188(02):480–484

32 Datta SN, Chaliha C, Singh A, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int 2008;101(02):192–196

33 Panicker JN, Seth JH, Khan S, et al. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler’s syndrome). BJU Int 2016;117 (05):809–813

34 Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 2001;20(02):138–143

35 Castel-Lacanal E, Gamé X, Clanet M, et al. Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. Neurolour Urodyn 2015;34(01):32–36

36 Fourtassi M, Jacquin-Courtois S, Scheiber-Nogueira MC, et al. Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation. Spinal Cord 2012;50(07):558–562

37 Kesslers TM. Diagnosis of urinary incontinence. JAMA 2008;300 (03):283, author reply 283

38 NICE. Urinary incontinence in neurological disease: assessment and management. Clinical guideline (CG148) 2012

39 Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80(05):470–477

40 Podnar S, Trsinar B, Vodusek DB. Bladder dysfunction in patients with cauda equina lesions. Neurolour Urodyn 2006;25(01):23–31

41 Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997;20(11):1396–1403

43 Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 2018;33(03):372–390

44 Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986;135(05):966–968

45 Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine Investigator Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity—results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007;51 (01):235–242

46 Mazo EB, Babinova GA. [Tropism chloride (Spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive bladder caused by vertebral lesions]. Urologia 2007;03:15–19

47 Ethans KD, Nance PW, Bard BJ, Casey AR, Schryvers OI. Efﬁcacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004;27(03):214–218

48 van Rey F, Heesakkers J, Solifencin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol 2011;2011:834753

49 Madhuvarpa P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 2012;62(05):816–830

50 Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efﬁcacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012;62(06):1040–1060

51 Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175(03):401–407

52 Risacher SL, McDonald BC, Tallman EF, et al. Alzheimer’s Disease Neuroimaging Initiative. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 2016;73(06):721–732

53 Fox C, Smith T, Maidment L, et al. Effect of medications with anticholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;43 (05):604–615

54 Davis TP, Sanchez-Covarrubias L, Tome ME. P-glycoprotein trafﬁcking as a therapeutic target to optimize CNS drug delivery. Adv Pharmacol 2014;71:25–44

55 Chancellor MB, Staskin DR, Kay GG, Sandage BW, Ofelelin MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging 2012;29(04):259–273

56 Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract 2010;64(09):1279–1286

57 Išik AT, Celik T, Bozoglu E, Doruk H. Tropism and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009;13(08):672–676

58 Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efﬁcacy, safety, and tolerability. Neurourou Urodyn 2014;33(01):17–30

59 Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efﬁcacy of mirabe- gron for patients with neurogenic lower urinary tract dysfunction. Neurourou Urodyn 2018;37(08):2810–2817

60 Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord 2018;57:22–26

61 Krhut J, Borovička V, Bílková K, et al. Efﬁcacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity—prospective, randomized, double-blind, placebo-controlled study. Neurourou Urodyn 2018;37(07):2226–2333

62 Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B. Efﬁcacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005;112(01):1–5

63 Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergics? Preliminary results. J Urol 2000;164(3, Pt 1):692–697

64 Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000;342 (09):665

65 Cruz F, Herschorn S, Aliotta P, et al. Efﬁcacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60(04):742–750

66 Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efﬁcacy and tolerability study of onabotulinumtoxinA for urinary
incontinence from neurogenic detrusor overactivity. J Urol 2012; 187(06):2131–2139

67 Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55(03):705–711

68 Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology 2013;81(03):491–497

69 Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010;183(04):1438–1443

70 Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol Urodyn 2009;28(01):62–67

71 Kabay S, Kabay SC, Yucel M, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn 2009;28(08):964–968

72 Gobbi C, Digesu GA, Khullar V, El Neil S, Caccia G, Zecca C. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Mult Scler 2011;17(12):1514–1519

73 Salatzki J, Liechti MD, Spanudakis E, et al. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder. BJU Int 2019;123(5A):E20–E28

74 de Sèze M, Raibaut P, Gallien P, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn 2011;30(03):306–311

75 Monteiro ES, de Carvalho LB, Fukujima MM, Lora MI, do Prado GF. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. Urology 2014;84(03):509–514

76 Phé V, Pakzad M, Curtis C, et al. Urinary tract infections in multiple sclerosis. Mult Scler 2016;22(07):855–861

77 Seth JH, Haslam C, Panicker JN. Ensuring patient adherence to clean intermittent self-catheterization. Patient Prefer Adherence 2014;8:191–198

78 Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003;17(01):42–47

79 Naumann M, So Y, Argoft CE, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review); report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1707–1714

80 Phé V, Pakzad M, Haslam C, et al. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol Urodyn 2017;36(07):1770–1775

81 Gallien P, Amarenco G, Benoit N, et al. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler 2014;20(09):1252–1259